> top > docs > PubMed:11800371 > annotations

PubMed:11800371 JSONTXT

Annnotations TAB JSON ListView MergeView

AIMed

Id Subject Object Predicate Lexical cue
T1 43-59 protein denotes cyclooxygenase-2
T2 422-438 protein denotes cyclooxygenase-2
T3 440-445 protein denotes COX-2
T4 633-638 protein denotes COX-2
T5 841-846 protein denotes COX-2
T6 1046-1051 protein denotes COX-2
T7 1202-1207 protein denotes COX-2
T8 1314-1319 protein denotes COX-2
T9 1390-1395 protein denotes COX-2
T10 1466-1471 protein denotes COX-2

DisGeNET

Id Subject Object Predicate Lexical cue
T0 633-638 gene:5743 denotes COX-2
T1 667-679 disease:C0027430 denotes nasal polyps
T2 1046-1051 gene:5743 denotes COX-2
T3 1150-1162 disease:C0027430 denotes nasal polyps
T4 1466-1471 gene:5743 denotes COX-2
T5 1564-1576 disease:C0027430 denotes nasal polyps
T6 1390-1395 gene:5743 denotes COX-2
T7 1564-1576 disease:C0027430 denotes nasal polyps
T8 1390-1395 gene:5743 denotes COX-2
T9 1399-1411 disease:C0027430 denotes nasal polyps
R1 T0 T1 associated_with COX-2,nasal polyps
R2 T2 T3 associated_with COX-2,nasal polyps
R3 T4 T5 associated_with COX-2,nasal polyps
R4 T6 T7 associated_with COX-2,nasal polyps
R5 T8 T9 associated_with COX-2,nasal polyps

FSU-PRGE

Id Subject Object Predicate Lexical cue
T1 14-38 protein denotes glucocorticoid receptors
T2 43-59 protein denotes cyclooxygenase-2
T3 387-411 protein denotes glucocorticoid receptors
T4 413-416 protein denotes GRs
T5 422-438 protein denotes cyclooxygenase-2
T6 440-445 protein denotes COX-2
T7 612-614 protein denotes GR
T8 633-638 protein denotes COX-2
T9 833-836 protein denotes GRs
T10 841-846 protein denotes COX-2
T11 894-896 protein denotes GR
T12 1046-1051 protein denotes COX-2
T13 1202-1207 protein denotes COX-2
T14 1314-1319 protein denotes COX-2
T15 1382-1385 protein denotes GRs
T16 1390-1395 protein denotes COX-2
T17 1466-1471 protein denotes COX-2

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-102 Sentence denotes Expression of glucocorticoid receptors and cyclooxygenase-2 in nasal polyps from nonallergic patients.
T2 103-195 Sentence denotes Glucocorticoid treatment has been widely used to suppress inflammatory and immune responses.
T3 196-336 Sentence denotes However, from a clinical point of view, its efficacy in the treatment of nasal polyposis seems to vary individually from patient to patient.
T4 337-524 Sentence denotes In the present study, we examined the presence of glucocorticoid receptors (GRs) and cyclooxygenase-2 (COX-2) in the nasal polyps of nonallergic patients as compared with normal controls.
T5 525-755 Sentence denotes Reverse transcription-polymerase chain reaction analyses revealed the presence of both GR messenger RNA and COX-2 messenger RNA expression in nasal polyps from nonallergic patients, as well as in normal nasal mucosa from controls.
T6 756-876 Sentence denotes Consistent with this finding, immunohistochemical analysis demonstrated that GRs and COX-2 were labeled in both tissues.
T7 877-1032 Sentence denotes In nasal polyps, GR labeling was associated with the cytoplasm and nucleus of surface mucosa, submucosal glands, endothelial cells, and inflammatory cells.
T8 1033-1163 Sentence denotes Importantly, COX-2 labeling was seen in the cytoplasm of surface mucosa, submucosal glands, and the vascular wall in nasal polyps.
T9 1164-1351 Sentence denotes In contrast, in normal nasal tissues, COX-2 labeling was only found in the vascular wall, and the expression was weaker--a finding demonstrating that COX-2 is upregulated in nasal polyps.
T10 1352-1677 Sentence denotes Therefore, 1) the presence of GRs and COX-2 in nasal polyps from nonallergic patients, as well as upregulation of COX-2 expression, suggests that inflammation may play an important role in the pathophysiology of nasal polyps; and 2) glucocorticoid could be a potential treatment method for suppressing inflammatory processes.
T1 0-102 Sentence denotes Expression of glucocorticoid receptors and cyclooxygenase-2 in nasal polyps from nonallergic patients.
T2 103-195 Sentence denotes Glucocorticoid treatment has been widely used to suppress inflammatory and immune responses.
T3 196-336 Sentence denotes However, from a clinical point of view, its efficacy in the treatment of nasal polyposis seems to vary individually from patient to patient.
T4 337-524 Sentence denotes In the present study, we examined the presence of glucocorticoid receptors (GRs) and cyclooxygenase-2 (COX-2) in the nasal polyps of nonallergic patients as compared with normal controls.
T5 525-755 Sentence denotes Reverse transcription-polymerase chain reaction analyses revealed the presence of both GR messenger RNA and COX-2 messenger RNA expression in nasal polyps from nonallergic patients, as well as in normal nasal mucosa from controls.
T6 756-876 Sentence denotes Consistent with this finding, immunohistochemical analysis demonstrated that GRs and COX-2 were labeled in both tissues.
T7 877-1032 Sentence denotes In nasal polyps, GR labeling was associated with the cytoplasm and nucleus of surface mucosa, submucosal glands, endothelial cells, and inflammatory cells.
T8 1033-1163 Sentence denotes Importantly, COX-2 labeling was seen in the cytoplasm of surface mucosa, submucosal glands, and the vascular wall in nasal polyps.
T9 1164-1351 Sentence denotes In contrast, in normal nasal tissues, COX-2 labeling was only found in the vascular wall, and the expression was weaker--a finding demonstrating that COX-2 is upregulated in nasal polyps.
T10 1352-1677 Sentence denotes Therefore, 1) the presence of GRs and COX-2 in nasal polyps from nonallergic patients, as well as upregulation of COX-2 expression, suggests that inflammation may play an important role in the pathophysiology of nasal polyps; and 2) glucocorticoid could be a potential treatment method for suppressing inflammatory processes.